Key result
Plasma miR-142 levels were negatively associated with clopidogrel active metabolite H4 Cmax (r = -0.5269; p = 0.0040) and H4 AUC0-4h (r = -0.4986; p = 0.0069) after a 300 mg loading dose.
Why the study?
Is plasma miR-142 associated with the pharmacokinetics of clopidogrel in patients with coronary heart disease?
Observational (n=31)
Is plasma miR-142 associated with the pharmacokinetics of clopidogrel in patients with coronary heart disease?
Plasma miR-142 levels are associated with clopidogrel pharmacokinetics and may account for some of the missing heritability in CYP3A4/5 functionality.
miR-142 association with lower clopidogrel metabolite exposure is hypothesis-generating; leaves open its role in CYP3A4/5 variability.
AIM: To investigate whether plasma miRNAs targeting CYP3A4/5 have an impact on the variance of pharmacokinetics of clopidogrel. MATERIALS & METHODS: The contribution of 13 miRNAs to the CYP3A4/5 gene expression and activity was investigated in 55 liver tissues. The association between plasma miRNAs targeting CYP3A4/5 mRNA and clopidogrel pharmacokinetics was analyzed in 31 patients with coronary heart disease who received 300 mg loading dose of clopidogrel. RESULTS: Among 13 miRNAs, miR-142 was accounting for 12.2% (p = 0.002) CYP3A4 mRNA variance and 9.4% (p = 0.005) CYP3A5 mRNA variance, respectively. Plasma miR-142 was negatively associated with H4 Cmax (r = -0.5269; p = 0.0040) and associated with H4 AUC0-4h (r = -0.4986; p = 0.0069) after 300 mg loading dose of clopidogrel in coronary heart disease patients. CONCLUSION: miR-142 could account for a part of missing heritability of CYP3A4/5 functionality related to clopidogrel activation.
No takes yet. Share an insight, caveat, or question.
Tang et al. (2016) conducted an observational in Coronary heart disease (n=31). Plasma miR-142 was evaluated on Clopidogrel pharmacokinetics (H4 Cmax and H4 AUC0-4h) (r = -0.5269 (H4 Cmax); r = -0.4986 (H4 AUC0-4h), p=0.0040 (H4 Cmax); 0.0069 (H4 AUC0-4h)). Plasma miR-142 levels were negatively associated with clopidogrel active metabolite H4 Cmax (r = -0.5269; p = 0.0040) and H4 AUC0-4h (r = -0.4986; p = 0.0069) after a 300 mg loading dose.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: